{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:01:47Z","timestamp":1779926507792,"version":"3.53.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"crossref","award":["LHGJ20210732"],"award-info":[{"award-number":["LHGJ20210732"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44313-x","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:52:32Z","timestamp":1775490752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world study of oral low-dose metronomic vinorelbine in elderly patients with metastatic triple-negative breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Jiayin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lige","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"44313_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/his.14091","author":"PH Tan","year":"2020","unstructured":"Tan, P. H. et al. The 2019 WHO classification of tumours of the breast. Histopathology https:\/\/doi.org\/10.1111\/his.14091 (2020).","journal-title":"Histopathology"},{"issue":"381","key":"44313_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"30","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple negative breast cancer. BMJ 30(381), e071674 (2023).","journal-title":"BMJ"},{"issue":"1","key":"44313_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 15(1), 121 (2022).","journal-title":"J Hematol Oncol."},{"issue":"9","key":"44313_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamaoncol.2023.2150","volume":"9","author":"E Munzone","year":"2023","unstructured":"Munzone, E. et al. Efficacy of metronomic oral vinorelbine, cyclophosphamide, and capecitabine vs weekly intravenous paclitaxel in patients with estrogen receptor-positive, ERBB2-negative metastatic breast cancer: final results from the phase 2 METEORA-II randomized clinical trial. JAMA Oncol. 9(9), 1267\u20131272 (2023).","journal-title":"JAMA Oncol."},{"issue":"15","key":"44313_CR5","first-page":"4342","volume":"63","author":"F Bartolini","year":"2003","unstructured":"Bartolini, F. et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63(15), 4342\u20134346 (2003).","journal-title":"Cancer Res."},{"issue":"8","key":"44313_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105(8), 1045\u20131047 (2000).","journal-title":"J. Clin. Invest."},{"key":"44313_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.breast.2021.08.004","volume":"59","author":"N Bianco","year":"2021","unstructured":"Bianco, N. et al. Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. a single institutional retrospective analysis. Breast 59, 351\u2013357 (2021).","journal-title":"Breast"},{"issue":"3","key":"44313_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10549-021-06375-5","volume":"190","author":"ME Cazzaniga","year":"2021","unstructured":"Cazzaniga, M. E. et al. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.[J]. Breast Cancer Res Treat. 190(3), 415\u2013424 (2021).","journal-title":"Breast Cancer Res Treat."},{"issue":"23","key":"44313_CR9","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-23-1267","volume":"29","author":"A Joaquin Garcia","year":"2023","unstructured":"Joaquin Garcia, A. et al. Differential benefit of metronomic chemotherapy among triple-negative breast cancer subtypes treated in the IBCSG trial 22-00.[J]. Clin Cancer Res. 29(23), 4908\u20134919 (2023).","journal-title":"Clin Cancer Res."},{"issue":"18","key":"44313_CR10","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1158\/1078-0432.CCR-23-0370","volume":"29","author":"H Tovey","year":"2023","unstructured":"Tovey, H. et al. Integrated multimodal analyses of DNA damage response and immune markers as predictors of response in metastatic triple-negative breast cancer in the TNT trial (NCT00532727). Clin. Cancer Res. 29(18), 3691\u20133705 (2023).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"44313_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13058-021-01392-0","volume":"23","author":"M Aine","year":"2021","unstructured":"Aine, M. et al. Molecular analyses of triple-negative breast cancer in the young and elderly. Breast Cancer Res. 23(1), 20 (2021).","journal-title":"Breast Cancer Res."},{"issue":"14","key":"44313_CR12","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1002\/cncr.32922","volume":"126","author":"D Ma","year":"2020","unstructured":"Ma, D. et al. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies. Cancer 126(14), 3209\u20133218 (2020).","journal-title":"Cancer"},{"issue":"16","key":"44313_CR13","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.3390\/jcm11164710","volume":"11","author":"ME Cazzaniga","year":"2022","unstructured":"Cazzaniga, M. E. et al. Metronomic chemotherapy for metastatic breast cancer treatment: clinical and preclinical data between lights and shadows. J Clin Med. 11(16), 4710 (2022).","journal-title":"J Clin Med."},{"issue":"17","key":"44313_CR14","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.7150\/jca.60682","volume":"12","author":"CT Liu","year":"2021","unstructured":"Liu, C. T. et al. Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study. J Cancer. 12(17), 5355\u20135364 (2021).","journal-title":"J Cancer."},{"issue":"9","key":"44313_CR15","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.3390\/cancers13092236","volume":"13","author":"ME Cazzaniga","year":"2021","unstructured":"Cazzaniga, M. E. et al. Metronomic chemotherapy. Cancers (Basel). 13(9), 2236 (2021).","journal-title":"Cancers (Basel)."},{"issue":"1\u20132","key":"44313_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000520236","volume":"45","author":"S Krajnak","year":"2022","unstructured":"Krajnak, S. et al. Metronomic chemotherapy for metastatic breast cancer. Oncol Res Treat. 45(1\u20132), 12\u201317 (2022).","journal-title":"Oncol Res Treat."},{"issue":"4","key":"44313_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.20892\/j.issn.2095-3941.2022.0702","volume":"20","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Combined chemo-endocrine therapy as a potential new option for HR+\/HER2- advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine. Cancer Biol Med. 20(4), 287\u2013296 (2023).","journal-title":"Cancer Biol Med."},{"issue":"1","key":"44313_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5301\/tj.5000207","volume":"101","author":"F De Iuliis","year":"2015","unstructured":"De Iuliis, F. et al. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori 101(1), 30\u201335 (2015).","journal-title":"Tumori"},{"issue":"4","key":"44313_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3816\/CBC.2010.n.039","volume":"10","author":"R Addeo","year":"2010","unstructured":"Addeo, R. et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer [J]. Clin Breast Cancer 10(4), 301 (2010).","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"44313_CR20","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.5301\/tj.5000543","volume":"103","author":"ME Cazzaniga","year":"2017","unstructured":"Cazzaniga, M. E. et al. Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study[J]. Tumori 103(1), e4\u2013e8 (2017).","journal-title":"Tumori"},{"issue":"5","key":"44313_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/PAS.0b013e31819437f9","volume":"33","author":"MZ Gilcrease","year":"2009","unstructured":"Gilcrease, M. Z. et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am. J. Surg. Pathol. 33(5), 759\u2013767 (2009).","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"44313_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","volume":"11","author":"R Yerushalmi","year":"2010","unstructured":"Yerushalmi, R. et al. Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol. 11(2), 174\u2013183 (2010).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44313-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44313-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44313-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:02:20Z","timestamp":1779922940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44313-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44313"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44313-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of he Third People\u2019s Hospital Of Zhengzhou. Informed consent for the collection of medical information was obtained from all patients. All procedures performed in the study were in accordance with the ethical standards of the institutional research committee. The patient consent was written informed consent, and that this study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical"}}],"article-number":"16491"}}